Breaking News

Financial Report: Lilly 3Q11

Revenues up 9%

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Lilly 3Q11 3Q Revenues: $6.1 billion (+9%) 3Q Earnings: $1.2 billion (-5%) YTD Revenues: $18.2 billion (+8%) YTD Earnings: $3.5 billion (-11%) Comments: Cymbalta sales were up 29% to $1.1 billion in the quarter. Humalog sales were up 20% to $593.2 million. Forteo and Strattera sales were also up 20% to $240.3 million and $153.2 million, respectively. Cialis sales were up 16% to $469.8 million. Alimta sales were up 12% to $629.7 million. Gemzar sales dropped 72% to $91.0 million due to gener...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters